Bristol-Myers Squibb Co., of New York, said it has notified the New York Stock Exchange (NYSE) of its intention to voluntarily delist its $2 convertible preferred stock from the NYSE, a decision driven by the low number of shares outstanding, low daily trading volume, listing fees and compliance administration costs
NYSE = New York Stock Exchange. @ This column reflects the shares outstanding following the offering, when disclosed. % Market capitalization is calculated based on the offering price
It's website, though, still prominently notes, "We are the first Chinese chemical and biological drug company to list on the New York Stock Exchange with IPO proceeds reaching $261 million...One involved a financial software company (Longtop Financial Technologies Ltd.) that was delisted by the New York Stock Exchange in August 2011
By Larry Schuster | BioWorld International | Wednesday, April 10, 2013
It's website, though, still prominently notes, "We are the first Chinese chemical and biological drug company to list on the New York Stock Exchange with IPO proceeds reaching $261 million...One involved a financial software company (Longtop Financial Technologies Ltd.) that was delisted by the New York Stock Exchange in August 2011
By Larry Schuster | BioWorld Today | Tuesday, April 9, 2013
CEO Thomas Okarma, who ran Geron for more than a decade, is shooting for the New York Stock Exchange, where the company's shares would be listed under the symbol "AST
By Marie Powers | BioWorld Today | Friday, April 5, 2013
Anaeropharma Science Inc., of Tokyo, initiated a Phase I trial of APS001F in U.S. patients with advanced or metastatic solid tumors whose disease is no longer responsive to available treatments. The dose-escalation trial is designed to evaluate the safety, tolerability and efficacy of APS001F, a living recombinant bifidobacterium designed to express the cytosine deaminase gene in tumors. The therapy is expected to limit the systemic toxicity of the antitumor agent 5-FU. Convergence
China Botanic Pharmaceutical Inc., of Harbin, China, said that on March 1, the company received notice from the staff of the New York Stock Exchange that the plan of compliance previously submitted to the exchange had been accepted with a compliance date of May 1
BioWorld International | Wednesday, March 13, 2013
China Botanic Pharmaceutical Inc., of Harbin, China, said that on March 1, the company received notice from the staff of the New York Stock Exchange that the plan of compliance previously submitted to the exchange had been accepted with a compliance date of May 1
Ablynx NV, of Ghent, Belgium, and Spirogen Ltd., of London, inked a research collaboration to evaluate the potential of a cancer drug conjugate combining Spirogen's cytotoxic drugs, pyrrolobenzodiazepines and associated linker technology, with Nanobodies generated using Ablynx's technology platform. Under the terms, Ablynx will provide access to Nanobodies against an undisclosed target, and Spirogen will provide access to its cytotoxic warheads and conjugation technologies. The collaboration
BioWorld International | Wednesday, February 27, 2013
following its 2012 acquisition of the Actavis Group, of Zug, Switzerland, and began trading Thursday on the New York Stock Exchange under the symbol ACT
The company said it would have needed to raise considerable additional capital in order to return to compliance with the New York Stock Exchange listing requirements
Senesco Technologies Inc., of Bridgewater, N.J., was notified that the New York Stock Exchange will delist its stock (NYSE:SNT) prior to the opening of trading on Nov. 21 , due to its inability to meet the exchange's continued listing requirements
The New York Stock Exchange and Nasdaq halted all trading Monday, and in Washington, a meeting of the FDA's Risk Management Advisory Committee, slated to discuss hydrocodone-containing drugs was postponed
By Catherine Shaffer | BioWorld Today | Tuesday, October 30, 2012
Puma did the same last year. (See BioWorld Today, Oct. 7, 2011, and April 10, 2006.) On Friday, Los Angeles-based Puma, newly listed on the New York Stock Exchange, watched the shares (NYSE:PBYI) blast off, closing at $22.38, up $6.88, or 44 percent, after going as high as $23.25
By Randy Osborne | BioWorld Today | Monday, October 22, 2012
Bristol-Myers Squibb Co., of New York, said it has notified the New York Stock Exchange (NYSE) of its intention to voluntarily delist its $2 convertible preferred stock from the NYSE, a decision driven by the low number of shares outstanding, low daily trading volume, listing fees and compliance administration costs